Toll-Like Receptors as Novel Therapeutic Targets for Ovarian Cancer by Muccioli, Maria et al.
International Scholarly Research Network
ISRN Oncology
Volume 2012, Article ID 642141, 8 pages
doi:10.5402/2012/642141
Review Article
Toll-LikeReceptorsas NovelTherapeuticTargets for
Ovarian Cancer
MariaMuccioli,1 LesleeSprague,2 Harika Nandigam,2
Michelle Pate,3 andFabianBenencia1,2,3
1Molecular and Cell Biology Program, Ohio University, Athens, OH, USA
2Biomedical Engineering Program, Russ College of Engineering and Technology, Ohio University, Athens, OH, USA
3Department of Biomedical Sciences, College of Osteopathic Medicine, Ohio University, Athens, OH, USA
Correspondence should be addressed to Fabian Benencia, benencia@ohio.edu
Received 20 October 2011; Accepted 10 November 2011
Academic Editors: D. Mezzanzanica, A. E. Pinto, and M. J. Turk
Copyright © 2012 Maria Muccioli et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ovarian cancer (OC) is an aggressive disease that aﬀects approximately 1 in 70 women and has a poor prognosis (<50%, 5-year
survivalrate),inpartbecause itisoftendiagnosedatalatestage.Therearethreemaintypes ofOC:neoplasmsofsurfaceepithelial,
germcell,orstromalorigin,withsurfaceepithelialtumorscomprisingabout80%ofallOCs.Inadditiontoimprovingdiagnostics,
it is necessary to develop more eﬀective treatments for epithelial-origin OC. Here, we describe the paradoxical roles of toll-like
receptor (TLR) signaling in the progression of cancer and discuss how its modulation may result in decreased tumor growth and
metastasis via the attenuation of proangiogenic cytokines and potentiation of proapoptotic factors. In particular, it has been found
that TLR activity can behave like a “double-edged sword”, as its signaling pathways have been implicated as having both tumor-
suppressive and tumor-promoting eﬀects. With particular emphasis on OC, we discuss the need to consider the signaling details of
TLRsandassociatedproteinsinthemultiplecelltypespresentinthetumormilieutoachievesafeandeﬀectivedesignofTLR-based
cancer therapies.
1.OvarianCancerDisease Characteristics
Ovarian cancer (OC) is characterized by malignant transfor-
mation of ovarian epithelial, stromal, or germ line cells. It
aﬀects approximately 1 in 70 women and has a poor progno-
sis (<50%, 5-year survival rate) [1]. Early-stage OC presents
no obvious symptoms in the majority of patients, and no
eﬀective screening method is available at the current time. As
aresult,OC is most commonlydiagnosed at stageIII orstage
IV. In later stages, metastasis often occurs, which can involve
the peritoneal surface and adjacent organs, lymph nodes,
lungs, and liver, among other sites. For these patients, the
outcome is poor, with an on average 20% long-term survival
rate [1].
OC can develop as a result of genetic risk factors, such as
mutations in BRCA1 and BRCA2 genes. However, less than
10% of OCs arise as a result of genetic predisposition. Other
nongenetic causes, such as chronic inﬂammation can result
inOCdevelopmentaswell[1].Ithasbeenshownthatahigh-
er number of pregnancies and oral contraceptive use corre-
lates to decreased OC risk, suggesting that limited ovulation
creates an environment that is less conducive to neoplasm
development. The most common tools used today in diag-
nostics include measurement of CA-125 levels in the serum,
pelvic ultrasonography, and biopstic and histochemical anal-
ysis. The downfall of the screening methodology is that not
all OCs exhibit elevated CA-125 levels, and this method has
proven to be rather unreliable in OC detection. By the time
clear symptoms are present, and a sonogram, biopsy, and
immunohistochemistry are performed, the OC is often in its
later stages.
Primary treatments of stage III and IV OC include sur-
gery, followed by several rounds of chemotherapy with radi-
ation rarely used [1]. Typically, a full hysterectomy and bilat-
eral salpingooophorectomy are performed. Chemotherapy
for OC usually includes platinum- and taxane-based agents,2 ISRN Oncology
with either three or six rounds of intravenous treatment
administered postoperatively. Platinum-containing drugs,
such as cisplatin act by binding to and cross linking DNA
and taxane-containing drugs, such as paclitaxel aﬀect micro-
tubular formation. Thereby, both agents thus act on the
tumor by preventing cell division.
Major problems encountered with current treatments
include chemotherapy side eﬀects and drug resistance. Side
eﬀects often include pain, nausea, vomiting, alopecia, and
neuropathy, among others. These side eﬀects typically arise
as a result of healthy cells being aﬀected by the treatment,
resulting in various organismal imbalances. In addition, re-
sistancetothedrugscandevelop,mostoftenasaresultofthe
cells rapidly eliminating the agent [2]. In order to improve
OC survival rates, it is necessary to investigate new targets
and therapies, which can be administered independently or
as adjuvants to the traditional methods of surgery and chem-
otherapy.
2. Inﬂammation and Cancer
Innate immunity is the ﬁrst response to an immunological
challenge, and the onset of an innate immune response
against pathogens and “danger signals” is very rapid. Macro-
phages, granulocytes, dendritic cells (DCs), and natural
killer (NK) cells are key immune cells that participate in
innate immune responses. After contacting pathogens, these
cells are able to eliminate them through several mechanisms,
such as phagocytosis or generation of reactive oxygen or
nitrogen species. DCs and macrophages are usually called
phagocytes due to their capability to engulf foreign material.
Pathogens are detected by phagocytes through the expres-
sion of conserved pathogen-associated molecular patterns
(PAMPs) present on the cell surface of the pathogen. These
molecules are detected by pattern recognition receptors
(PRRs) expressed on immune cells [3]. Through PRR recog-
nition, the phagocytes of the innate immune response are
able to distinguish between self and foreign non-self cells.
Some of the main PRRs involved in the innate immune res-
ponse are toll-like receptors (TLRs) and NOD-like receptors
(NLRs) [3–5].
An example of the innate immune response is the initia-
tion of inﬂammation. A microorganism displaying PAMPs
which has become resident within body tissues can be
recognized by macrophage PRRs [3]. When this occurs, the
phagocyte will internalize the microorganism by phagocy-
tosis, become activated, and eliminate the microorganism.
However, in addition to eliminating the microorganism,
the activated macrophage will also begin to secrete pro-
teins known as cytokines and chemokines. Cytokine and
chemokine release can lead to increased vascular permeabil-
ity and expression of cellular adhesion molecules, which can
in turn increase neutrophil and monocyte recruitment and
inﬁltration to the site of infection, thereby leading to an
overall ampliﬁcation of the inﬂammatory response [6, 7].
These cytokines are known as proinﬂammatory cytokines
[8]. Some examples of proinﬂammatory cytokines include
interleukin (IL)-1, IL-6, and and tumor necrosis factor-alpha
(TNF-α)[ 8, 9]. Through cytokine and chemokine release,
additional immune cells can be recruited to the area of in-
fection and cause the classical symptoms of inﬂammation:
swelling, redness, heat, and pain.
Infection, chronic irritation and inﬂammation are
among the main causes for the initiation of diﬀerent types of
cancer [10]. Indeed, inﬂammatory cells can contribute to the
proliferation, survival, and migration of tumor cells and also
play an important role in shaping the tumor microenviron-
ment [10]. It has been demonstrated that chronic inﬂamma-
tion and cancer are often interrelated [11]. Smoking for
instanceis associatedwithchronic inﬂammationofthelungs
and with lung cancer, and alcohol abuse has been linked to
inﬂammation and cancer of the liver and the pancreas [12].
The relationship between inﬂammation and cancer is com-
plex, and inﬂammation can have either tumor-promoting or
tumor-suppressive eﬀects, depending on the type of inﬂam-
mation. Thus, the ﬁeld of tumor immunology is an im-
portant part of the ongoing eﬀorts of improving cancer
treatments.
3. Inﬂammation andthe
Tumor Microenvironment
Tumors are more than cancer cells, being also composed
of non-tumor cells (leukocytes, endothelial cells, ﬁbroblasts,
and smooth muscle cells) and the extracellular matrix.
Together with the tumor cells, they constitute the tumor mi-
croenvironment. The cytokine proﬁle of the tumor microen-
vir onmentislargelyaresultoffactorspr oducedbythetumor
cells themselves, nearby cells, and inﬁltrating white blood
cells and can have profound eﬀects on tumor progression
[13]. Some cytokines can inﬂuence the tumor microenviron-
ment in such a way that will suppress tumor development,
while others can contribute to its growth and metastasis.
UpregulationofIL-12,forexample,willactivateNKcellsand
cytotoxic T lymphocytes, resulting in cancer cell death [12].
In addition, induction of IL-23 leads to the production of
interferons(IFNs)andothertumor-suppressivefactors.Such
molecules are activated as part of the antitumor immunity
response and promote apoptosis of tumor cells.
In the case of chronic inﬂammation, the cytokine proﬁle
at the tumor microenvironment is dramatically diﬀerent and
is characterized by an increase in immunosuppressive cyto-
kines, such as TNF-α and IL-6 [12]. These cytokines can
activate pathways that result in production of other inﬂam-
matory molecules, capable of recruiting leukocytes, such as
macrophages and DCs to the tumor site. These inﬁltrating
leukocytes in turn can produce factors which aid in the
promotionofangiogenesisandvascularization,subsequently
contributing to tumor growth and metastasis [11].
Angiogenesis is critical to cancer growth, as it allows for
growing vasculature that will provide suﬃcient nutrients to
thetumortopromoteitsgrowth[11].Chronicinﬂammation
can create an environment in the tumor milieu that is con-
ducive to the formation of new blood vessels and thereby
facilitates tumor progression. In addition to proangiogenic
factors that arise from leukocyte inﬁltration, the tumor cells
themselves produce soluble factors that potentiate angio-
genesis and secrete proinﬂammatory cytokines, which canISRN Oncology 3
indirectly stimulate tumor growth [12]. As angiogenesis is a
relevant process in cancer progression, pathways that trigger
it are being investigated for potential drug targets for devel-
opment of antiangiogenic therapeutics.
A major proinﬂammatory switch that can subsequently
result in proangiogenic stimuli is nuclear factor-kappa B
(NF-κB). NF-κB comprises a family of transcription factors
that regulates the production of various cytokines, chemo-
kines, and antiapoptotic and stress-response factors [14].
Diﬀerent NF-κB proteins can bind to speciﬁc sites on the
DNA to inﬂuence transcription of a multitude of inﬂamma-
tory response genes. The transcription factors reside in the
cytoplasm, in complex with inhibitors of NF-κB( I κBs) and
are released, upon phosphorylation of the IκBs by inhibitor
of NF-κB kinase (IKK). At this point, the IκBs become
degraded and the transcription factors are able to translocate
into the nucleus to regulate inﬂammatory responses. The
NF-κB proteins regulate inﬂammation by binding to speciﬁc
DNA sites and upregulating or downregulating the amounts
of histone remodeling proteins at the site. Some inﬂam-
m a t o r yg e n e sw h i c ha r eu p r e g u l a t e db yN F - κB include a
multitude of proinﬂammatory cytokines and chemokines,
matrix metalloproteases, adhesion factors, cyclooxygenase 2,
and inducible nitric oxide synthase. Upregulation of these
molecules results in the recruitment of immune cells and the
increased production of proinﬂammatory molecules.
It has been shown that constitutive activation of NF-κB
is associated with cancer progression [15]. Speciﬁcally, it can
lead to promotion of angiogenesis and increased metastasis
by producing chemokines, such as IL-8 that promote leu-
kocyte inﬁltration and inﬂammation and increased levels of
MMPs that promote tumor invasion of nearby tissue. Also,
NF-κB can upregulate factors like TNF-α, which can result in
inhibition of apoptosis and also stimulates cell proliferation
by increasing transcription of molecules such as IL-2 and
granulocyte-macrophage colony-stimulating factor (GM-
CSF). In addition, certain members of the NF-κB family can
also activate proapoptotic factors [16].
NF-κB has thus been considered a major target for anti-
cancer therapies. Often treatment results were poor, as
NF-κB proteins participate in many critical cell cycle func-
tions, the broad-scale disruption of which can lead to a
multitude of undesirable side eﬀects [14]. It is thus necessary
to investigate potential regulators of NF-κB, which might
be drug-target candidates for the development of tumor-
targeted, antiangiogenic, and proapoptotic treatments.
4.Toll-Like Receptors andCancer
TLRs are a family of integral membrane proteins which act
as sensors of invading pathogens and primarily reside in
immune cells, such as DCs and macrophages [17]. Present
either at the cell surface membrane or at the endosomal
membrane,TLRsrecognizespeciﬁcPAMPsandinitiateasig-
naling cascade to elicit an immune response. As depicted in
Figure 1, all TLRs have two domains: a leucine-rich domain
that senses the pathogen and a Toll-interleukin 1 receptor
(TIR) domain which interacts with an adapter molecule to
initiate a signaling cascade to promote an immune response.
TIR signal 
transduction 
domain  
Cellular or 
endosomal 
membrane
Leu-rich pathogen-
recognition domain
Figure 1: Schematic TLR Structure. TLRs are typically transmem-
brane receptors present in cellular or endosomal membranes, char-
acterizedbyaleucine-richpathogen-recognitiondomainandatoll-
interleukin 1 receptor (TIR) signal transduction domain.
Over ten types of TLRs have been identiﬁed in vertebrates,
categorization primarily based on their PAMP recognition
patterns. Diﬀerent TLRs recognize diﬀerent PAMPs, such
as protein, nucleic acid, or lipid components of bacteria or
viruses. TLR4 for example, recognizes primarily bacterial
components, such as lipopolysaccharide, while others, such
as TLR3 recognizes dsRNA [18]. Upon recognition of the
foreignpathogens, TLRssignalthroughadapter moleculesin
a signaling cascade, which ultimately results in a change in
the cytokine expression patterns of those cells (Figure 2).
Several adapter molecules have been characterized in the
TLR family, and diﬀerent TLRs signal through one of four
adapters: MYD-88, MYD-88 adaptor-like (Mal), TIR-related
adaptor protein inducing interferon (TRIF), or TRIF-related
adapter protein molecule (TRAM) [18]. These adaptors
initiate distinct signaling cascades which usually lead to
activation of NF-κB.
Recently, TLRs have been implicated in tumor progres-
sion. It is becoming evident that tumor cells are capable of
exploiting TLR signaling pathways to their advantage [19].
It has been shown that TLR ligands can promote tumor
development by stimulating inﬂammation, particularly
through NF-κBa c t i v a t i o n[ 18, 19]. Between tumor cells and
inﬁltrating immune cells that express TLRs, these PRRs may
be partially responsible for the constitutive activation of NF-
κB, which is often seen in cancers. If ligands are present to
activateTLRsinthetumormilieu,thiscanleadtoanarrayof
cytokines capable of promoting angiogenesis. Interestingly,
TLR ligands have also been shown to possess tumor-sup-
pressive eﬀects via activation of pathways that result in pro-
motion of innate and adaptive antitumor responses [19].
Therefore, TLRs are signiﬁcant to tumor progression and
theireﬀectsontumordevelopmentarebeingevaluated.They
have thus become major players in the search for novel anti-
tumor drug targets.
5. TLRs as Therapeutic Targets for
Tumor Therapies
While TLRs are predominantly expressed in immune cells, in
the last years it has been shown that they are also expressed
in a variety of tumor cells where they are functional and
can help shape the inﬂammatory proﬁle of the tumor milieu
[19]. Thus, the therapeutic use of TLR agonists has been4 ISRN Oncology
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Figure 2: Schematic representation of some TLR signaling adaptors some downstream eﬀects. Upon interaction with their ligands, TLR can
induce a signaling cascade that can lead to generation of inﬂammatory molecules upon NF-κB or IRF3 activation.
investigated in several cancer models in order to either target
tumor cells or immune cells present in the tumor microen-
vironment. The rationale being to either induce apoptosis of
tumor cells or to activate resident immune cells that can help
mount a robust antitumor response. No conclusive results
have been obtained supporting the therapeutic use of TLR
agonists. Positive results have been obtained by using TLR
agonists as adjuvants for DC vaccination in murine models
of sarcoma (TLR3/9 agonists) [20], lung cancer (TLR9) [21],
and melanoma and brain cancer (TLR7/8 agonist) [22, 23].
It has also been shown that TLR agonists can enhance the
eﬃcacy of T-cell adoptive therapy by promoting a better
interaction between T cells and resident activated DCs [24].
In addition, direct targeting of TLR9 in cancer cells triggered
tumor cell death and an increase in survival in a xenograft
model of neuroblastoma [25].
On the contrary, TLR signaling in cancer cells can
promote tumor progression. In particular, diﬀerent TLR
agonistswereabletoinducemigrationofhumantumorcolo-
rectal, breast, lung, and glioblastoma cells, an indication of
metastatic potential [26]. Further, TLR signaling has been
associated with increased human myeloma and lung cells
proliferation and viability [27, 28].
6. OvarianCancer Microenvironment
These contradictory observations might be a result of the
complex nature of the tumor microenvironment. As we have
previously reviewed in detail, the ovarian cancer microen-
vironment is highly immunosuppressive [29]. For example,
high levels of IL-4, IL-10, transforming growth factor beta
(TGF-β), and vascular endothelial growth factor (VEGF)
can be found in ovarian cancer ascites [30, 31]. IL-4, IL-10,
and TGF-β can aﬀect phagocyte function, suppressing ma-
crophage and DC activity [32]. Indeed, DCs showing low
levels of costimulatory molecules have been detected in
tumors expressing high levels of VEGF [33]. These DCs are
able to render T cells anergic or tolerised, thus abrogating
antitumor immune responses. Interestingly, besides an im-
mune “paralysis”, we and others have shown that tumor-
associated DCs, or leukocytes expressing DC markers, are
able to produce angiogenic factors and can promote neovas-
cularization in the tumor microenvironment [34–36]. Our
previous work unveiled a mechanism whereby immature
DCs contribute to ovarian cancer progression by acquiring
a proangiogenic phenotype in response to VEGF [36, 37].
Further, we have shown that speciﬁc depletion of tumor-
associated DCs reduces ovarian cancer angiogenesis and
growth [38]. Interestingly, high amounts of CD4+CD25+
regulatory T cells have been described in ovarian carcinoma
and ascites, with the capability of suppressing antitumor im-
mune responses [39, 40]. In addition, as we have previously
shown, tumor endothelium can contribute to the immune
suppressive status of ovarian cancer microenvironment,
impairing cytotoxic T-cell inﬁltration [41]. On the other
hand, it has been shown that ovarian cancer is capable of
inducing antitumor immune responses, and that cytotoxicISRN Oncology 5
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Figure 3: Schematic representation of TLR3 Signaling. TLR3 present in the endosomal particles recognizes dsRNA and interacts through
cytoplasmic TRIF activating diﬀerent signaling pathways.
T-cell inﬁltration in ovarian cancer correlates with a better
prognosis [42].
The presence of several cellular leukocyte populations in
the microenvironment of ovarian cancer argues for speciﬁc
targeting of tumor microenvironment components when
applying TLR agonist therapies for cancer. For example, TLR
agonists can be prepared for their delivery to particular cells
within the tumor microenvironment [43]. This type of strat-
egy was successfully used to activate tumor-associated DCs
in ovarian cancer, promoting antitumor immune response
in vivo [44, 45].
7.TLRs andOvarianCancer
Speciﬁcally for ovarian cancer, Zhou and colleagues [46]
have shown show that TLR2, TLR3, TLR4, and TLR5 are
highly expressed on the normal ovarian epithelium, as well
as on neoplastic ovarian epithelial cells. Further, it has been
recently shown that TLR4 is also expressed in granulosa
tumor cells in the ovary [47]. In addition, it has also been
demonstrated that TLR9 expression is associated with poor
diﬀerentiationinovariancancerspecimens,andthatitsover-
expression and stimulation enhances the migratory capacity
of ovarian cancer cells [48].
Importantly, TLR4 expression in ovarian cancer cells has
been shown to exert protumor activities and to hamper the
eﬃcacy of paclitaxel therapy [49, 50]. This is caused by the
ability of paclitaxel to interact with this TLR, activating the
MyD88 signaling pathway and inducing the generation of
tumor cell survival and proliferation [49–51]. This pathway
points to a mechanism by which infections can promote
tumor progression by stimulating cancer cells to generate in-
ﬂammatory cytokines. TLR4 interacts with products of bac-
terial infection, but signaling through other TLRs in cancer
cells can generate similar responses. To investigate this, we
decided to use the MyD88 negative A2780 human ovarian
cancer cell line [50, 51] to stimulate it via TLR3. This TLR
is a largely endosomal PRR that recognizes dsRNA, such as
viral RNA, and may also be able to recognize intrinsic
dsRNA, such as that which can arise from normal events like
cell lysis, for example [17, 52]. While TLR3 has no known
endogenous ligands, it is suspected that various dsRNA
duplexes can activate it, and synthetic dsRNA analogs which
successfully bind to and stimulate TLR3 signaling have been
developed [52]. One of these synthetic ligands is polyino-
sinic: polycytidylic acid (poly [I:C]) which has been used
for many years to stimulate TLR3. As poly(I:C) has been
the “gold standard” ligand for TLR3 stimulation, in vitro6 ISRN Oncology
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Figure 4: Stimulation of A2780 ovarian cancer cells via TLR3. A270 human ovarian cancer cells were treated for 24h with 10μg/mL of
poly(I:C) (Invivogen, San Diego, CA) admixed with lipofectamine (Invitrogen, Carlsbad, MA) following the manufacturer’s instructions.
Then supernatants were recovered for analysis. Supernatants from two independent experiments were pooled, and the presence of diﬀerent
chemokines and cytokines in poly(I:C) treated (a) or controls (b) was analyzed by using the RayBio Human Cytokine Antibody Array 3
(RaybiotechInc,Norcross,GA)followingthemanufacturer’sinstructions.Finally,densityvalueswereanalyzedbyusingtheImageJprogram.
studies have been carried out using this ligand to investigate
the TLR3 signaling pathways in immune cells. It has been
demonstrated that poly (I:C) can directly cause apoptosis in
tumor cells in a caspase-dependent manner [16]. Interest-
ingly,itwasfoundthatcertainNF-κBproteinsmustbeactive
forthisTLR3-mediatedapoptosis.Poly(I:C)hasindeedbeen
tried as an adjuvant to chemotherapy, but it was found that
it was too toxic to be used for therapy [16, 52].
As shown in Figure 3, TLR3 signaling can activate NF-κB
in a MyD88-independent way. Upon stimulation with
poly(I:C), TLR3 signals through adapter TRIF (TICAM-1)
to initiate a signaling cascade that can activate transcription
factors NF-κB and interferon regulatory factor 3 (IRF3), as
wellastheJNKandp38pathways.TRIFisthelargestadaptor
known of the TLR adapters and can initiate several distinct
signalingcascades[52].TRIFhasanN-terminalregioncalled
the eﬀector-driving site, which is able to recruit the TNF
receptor-associatedfactor(TRAF)familyproteinstoresultin
the eventual activation of IRF3 and NF-κB. IRF3 activation
can result in the upregulation of α-a n dβ-type interferons
(IFNs)andactivationofcytotoxic lymphocytes andNKcells,
while NF-κB can either upregulate certain cytokines and
potentiate chronic inﬂammation and angiogenesis, or act
to promote apoptosis, depending on the particular NF-κB
membersthatareactivated.TRIFalsohasaC-terminalbind-
ingsite,whichcanrecruitfactorssuchasreceptorinteracting
protein (RIP-1) and Fas-associated death domain (FADD),
the signaling pathways of which result in apoptosis and auto-
phagy through the activation of the JNK and p38 pathways.
Thus TLR3 signaling can contribute to tumor eradication
v i au p r e g u l a t i o no fI F N - α and IFN-β, CTL, and NK cell
activation, and by signaling through the RIP-1/FADD path-
way, whereas it can also indirectly contribute to tumor
progression via activation of NF-κB, which can result
in proangiogenic factors and subsequent tumor progression.
As shown in Figure 4, 24h treatment of human ovarian can-
cer A2780 cells with 10μg/mL of poly(I:C) admixed with
liposomes is able to induce upregulation of several cytokines
and chemokines, IL-6 among others, which has been shown
to promote tumor cell growth and survival [53].ISRN Oncology 7
Altogether these data indicate that the non-targeted use
of TLR agonists for ovarian cancer therapy can generate
adverse eﬀects. Thus, targeted therapies to activate only par-
ticular components of the tumor microenvironment will be
more suitable. In this context, pioneering research from Dr.
Conejo-Garcia’s lab has shown in a murine model of ovarian
carcinoma that speciﬁcally targeting TLRs in tumor-asso-
ciatedantigen-presentingcellscaninducearobustantitumor
immune response and tumor regression [44, 45, 54, 55].
8. FinalRemarks
In closing, it is necessary to further elucidate all the distinct
signaling pathways of TLR in both tumor and immune cells
in order to develop eﬀective and safeimmunotherapies using
this target. On the one hand, TLR stimulation can result in
apoptosis, but on the other, it can lead in proangiogenic fac-
tors, which can stimulate tumor growth. Eﬀectively being
able to select for and speciﬁcally turn on and oﬀ these path-
waysistheultimategoal.AsdetailsconcerningTLRsignaling
in tumor cells and immune cells are clariﬁed, it may be
possible to design therapeutic agents, which target speciﬁc
pathways in speciﬁc cells and create a proapoptotic, antian-
giogenic tumor microenvironment, which is conducive to
tumor eradication.
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